Tormod K Guren

List of Publications by Year
in descending order

53	1,281	471371 17	395590 33
papers	citations	h-index	g-index

53	53	53	1756
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ipilimumab in a realâ€world population: A prospective Phase <scp>IV</scp> trial with longâ€term followâ€up. International Journal of Cancer, 2022, 150, 100-111.	2.3	11
2	Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 342-351.	1.1	7
3	Multiplex immunohistochemistry of metastatic colorectal cancer and ex vivo tumor avatars. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188682.	3.3	1
4	Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. The Lancet Gastroenterology and Hepatology, 2022, 7, 446-454.	3.7	36
5	First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours. British Journal of Cancer, 2022, 126, 1010-1017.	2.9	8
6	Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis. British Journal of Cancer, 2022, 127, 500-513.	2.9	15
7	A national precision cancer medicine implementation initiative for Norway. Nature Medicine, 2022, 28, 885-887.	15.2	7
8	Prototype precision oncology learning ecosystem: Norwegian precision cancer medicine implementation initiative.. Journal of Clinical Oncology, 2022, 40, e13634-e13634.	0.8	2
9	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600Eâ€“Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology, 2021, 39, 273-284.	0.8	254
10	Clinicopathological factors associated with tumourâ€specific mutation detection in plasma of patients with <scp>RAS</scp>â€mutated or <scp>BRAF</scp>â€mutated metastatic colorectal cancer. International Journal of Cancer, 2021, 149, 1385-1397.	2.3	10
11	Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. Frontiers in Immunology, 2021, 12, 663865.	2.2	17
12	Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respiratory Medicine,the, 2021, 9, 613-621.	5.2	44
13	Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 572172.	2.2	21
14	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. Clinical Cancer Research, 2020, 26, 4107-4119.	3.2	68
15	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. Journal of Clinical Oncology, 2020, 38, 4001-4001.	0.8	35
16	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. Journal of Clinical Oncology, 2020, 38, 4039-4039.	0.8	5
17	Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.. Journal of Clinical Oncology, 2020, 38, 1-1.	0.8	19
18	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. Journal of Clinical Oncology, 2020, 38, 8-8.	0.8	25

#	Article	IF	Citations
19	A phase I/IIa clinical trial investigating the therapeutic cancer vaccine UV1 in combination with ipilimumab in patients with malignant melanoma: Four-year survival update.. Journal of Clinical Oncology, 2020, 38, 62-62.	0.8	2
20	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 121, 144-153.	1.3	27
21	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 119, 168-178.	1.3	61
22	Combination therapies with HSP90 inhibitors against colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 240-247.	3.3	81
23	Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation â€“ a retrospective study. Transplant International, 2019, 32, 1144-1150.	0.8	23
24	Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies.. Journal of Clinical Oncology, 2019, 37, 2504-2504.	0.8	5
25	Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 395-405.	1.4	10
26	Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients. Acta OncolÃ³gica, 2018, 57, 1414-1418.	0.8	19
27	Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. British Journal of Cancer, 2018, 118, 1609-1616.	2.9	47
28	ISO-CC-005: A phase I/II study of Modufolin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin Â± bevacizumab in patients with metastasizing colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 838-838.	0.8	0
29	Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. British Journal of Cancer, 2017, 116, 1271-1278.	2.9	55
30	Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. European Journal of Cancer, 2017, 81, 26-35.	1.3	13
31	Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. International Journal of Cancer, 2017, 140, 431-439.	2.3	4
32	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. Journal of Clinical Oncology, 2017, 35, 9524-9524.	0.8	17
33	Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).. Journal of Clinical Oncology, 2016, 34, 3544-3544.	0.8	79
34	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. Journal of Clinical Oncology, 2016, 34, 9526-9526.	0.8	2
35	TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. Oncotarget, 2016, 7, 59441-59457.	0.8	7
36	Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget, 2016, 7, 75013-75022.	0.8	61

#	Article	IF	Citations
37	Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. International Journal of Cancer, 2015, 137, 2470-2477.	2.3	8
38	C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study.. Journal of Clinical Oncology, 2015, 33, 3548-3548.	0.8	0
39	Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study. PLoS ONE, 2014, 9, e87746.	1.1	18
40	Outcome after liver transplantation compared with chemotherapy in colorectal cancer patients with nonresectable liver-only disease.. Journal of Clinical Oncology, 2014, 32, 531-531.	0.8	0
41	Digitalized multiparametric analyses of tumor stroma for identification of low perivascular PDGFBR expression and low vessel density as independent prognosis markers for stage IV CRC.. Journal of Clinical Oncology, 2014, 32, e14525-e14525.	0.8	0
42	Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-1 level: Results from the NORDIC VII study.. Journal of Clinical Oncology, 2014, 32, 3590-3590.	0.8	0
43	Plasma levels of TIMP-1 in chemo-naive patients with metastatic colorectal cancer treated with first-line FLOX with or without cetuximab: Results from the Nordic VII Study.. Journal of Clinical Oncology, 2013, 31, 392-392.	0.8	0
44	Plasma TIMP-1 in patients with metastatic colorectal cancer treated with first-line oxaliplatin-based therapy with or without cetuximab: Results from the Nordic VII study.. Journal of Clinical Oncology, 2013, 31, e14710-e14710.	0.8	0
45	On-treatment progression-free survival analysis of ziv-aflibercept/FOLFIRI treatment within 28 days of end of treatment in metastatic colorectal cancer: Updated efficacy results from the VELOUR study.. Journal of Clinical Oncology, 2013, 31, 3573-3573.	0.8	0
46	Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3597-3597.	0.8	0
47	Tumor perivascular PDGFBR as an independent prognostic factor in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3571-3571.	0.8	0
48	Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2012, 30, 3531-3531.	0.8	8
49	Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study.. Journal of Clinical Oncology, 2012, 30, 3548-3548.	0.8	0
50	EGF receptor-mediated, c-Src-dependent, activation of Stat5b is downregulated in mitogenically responsive hepatocytes. Journal of Cellular Physiology, 2003, 196, 113-123.	2.0	17
51	Response to transforming growth factor Î± (TGFÎ±) and epidermal growth factor (EGF) in hepatocytes: Lower EGF receptor affinity of TGFÎ± is associated with more sustained activation of p42/p44 mitogen-activated protein kinase and greater efficacy in stimulation of DNA synthesis. , 1998, 175, 10-18.		55
52	Dual effects of glucagon and cyclic amp on dna synthesis in cultured rat hepatocytes: Stimulatory regulation in early G1 and inhibition shortly before the s phase entry. Journal of Cellular Physiology, 1990, 144, 523-530.	2.0	47
53	Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. Oncotarget, 0, 7, 41948-41958.	0.8	30